Usage and dosage of pomalidomide

Pomalidomide (Pomalidomide) is an immunomodulator that is widely used to treat diseases such as multiple myeloma (MM) and Kaposi's sarcoma (KS). Its main role is to relieve symptoms and improve patients' quality of life by regulating the immune system, anti-tumor effects and improving bone marrow function. The usage and dosage of pomalidomide need to be adjusted according to the specific conditions of the patient, and some patients may need personalized dosage adjustment based on liver and kidney function.

1. Usage of multiple myeloma (MM)

The recommended dose of pomalidomide for adults with multiple myeloma is 4 mg daily Patients typically take the drug daily on days 1 to 21 during a 28-day treatment cycle. After each cycle, patients need to rest for 7 days before entering the next cycle. Pomalidomide is usually continued until disease progression or unacceptable toxicity occurs. Patients should undergo regular blood routine examinations and liver and kidney function assessments during treatment to ensure the safety of treatment.

2. Usage of Kaposi's sarcoma (KS)

For patients with Kaposi's sarcoma, the recommended dose of pomalidomide is 5 mg per day, and treatment is also carried out according to a 28-day cycle, with oral administration daily from days 1 to 21. Similar to the treatment of multiple myeloma, treatment of patients with Kaposi's sarcoma is continued until disease progression or unacceptable toxicity occurs. Since patients with Kaposi's sarcoma have severely impaired immune function, patients need to pay special attention to changes in the immune system and take corresponding protective measures during treatment.

3. Other dosage adjustments

The dosage of pomalidomide may need to be adjusted based on the patient's liver and kidney function. For patients with renal or hepatic insufficiency, the dose should be adjusted individually based on the patient's specific conditions and clinical manifestations. Often, patients with poor hepatic and renal function may need to reduce their dose or suspend their medication until symptoms improve.

Keyword tags: pomalidomide,Pomalidomide, treatment regimen, multiple myeloma, Kaposi's sarcoma, dose, liver and kidney function, immune regulation, drug adjustment

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b25ef01-5c9e-11e1-b86c-0800200c9a66